| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8661787 | International Journal of Cardiology | 2018 | 5 Pages |
Abstract
PCSK9i are an effective alternative for those with existing CVD or at high risk of CVD in whom statin therapy alone is ineffective, but are not cost-effective to the Australian healthcare system based on current prices.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Radya Kumar, Andrew Tonkin, Danny Liew, Ella Zomer,